Flowbone develops an injectable bioactive hydrogel that promotes in‑situ bone mineralization to strengthen hip regions at high risk of fracture. The platform integrates with native bone biology, preserving vascularization and biomechanics without leaving foreign material. By delivering the gel minimally invasively via cannula, it aims to reduce osteoporotic hip fractures and associated healthcare costs.
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Osteoporosis affects millions worldwide, leading to decreased bone mass and increased fracture risk, particularly in the elderly. Current treatments often lack the ability to rapidly and locally strengthen fragile bones, leaving a critical gap in preventing imminent fractures in high-risk patients.
Solution
flowbone is developing an injectable, bone-seeding gel designed to quickly and subtly strengthen fragile bones locally. Once injected into a high-risk bone region, the gel initiates the deposition of the body's own minerals, transforming into strong, viable bone. This biomaterial solution complies with bone biology, avoiding foreign materials and interference with bone vascularization and biomechanics. The minimally invasive procedure involves injecting the gel with a cannula, offering a targeted approach to fracture prevention.
Target Audience
The primary target audience includes bone specialists treating patients at high risk of osteoporotic fractures, particularly elderly individuals seeking to maintain independence and quality of life.
Features
- Injectable gel that promotes rapid bone regeneration through the deposition of the body's own minerals.
- Biocompatible material designed to integrate seamlessly with existing bone structure.
- Minimally invasive delivery via cannula injection.
- Targeted local strengthening of bones at high risk of fracture.